306, F1210-1221.
2) Kaneyama, T., Tomiki, H., Tsugane, S., Inaba, Y., Ichikawa, M., Akiba, H., Yagita, H., Kim, B. S., and Koh, C. S. (2014) The TIM-3 pathway ameliorates Theiler's murine encephalomyelitis virus-induced demyelinating disease. Int Immunol 26, 369-381.
3) Kamachi, F., Harada, N., Usui, Y., Sakanishi, T., Ishii, N., Okumura, K., Miyake, S., and Akiba, H. (2014) OX40 ligand regulates splenic CD8- dendritic cell-induced Th2 responses in vivo. Biochem Biophys Res Commun 444, 235-240.
2013
1) TIM-4 has dual function in the induction and effector phases of murine arthritis.
Abe Y, Kamachi F, Kawamoto T, Makino F, Ito J, Kojima Y, Moustapha Ael D, Usui Y, Yagita H, Takasaki Y, Okumura K, Akiba H.
J Immunol. 2013;191(9):4562-72.
2) Interruption of dendritic cell-mediated TIM-4 signaling induces
regulatory T cells and promotes skin allograft survival. Yeung MY,
McGrath MM, Nakayama M, Shimizu T, Boenisch O, Magee CN, Abdoli R,
Akiba H, Ueno T, Turka LA, Najafian N. J Immunol. 2013;191(8):4447-55.
3) TIM-4 glycoprotein-mediated degradation of dying tumor cells by
autophagy leads to reduced antigen presentation and increased immune
tolerance. Baghdadi M, Yoneda A, Yamashina T, Nagao H, Komohara Y,
Nagai S, Akiba H, Foretz M, Yoshiyama H, Kinoshita I, Dosaka-Akita H,
Takeya M, Viollet B, Yagita H, Jinushi M. Immunity. 2013;39(6):1070-81.
4) Monocyte-derived dendritic cells perform hemophagocytosis to
fine-tune excessive immune responses. Ohyagi H, Onai N, Sato T,
Yotsumoto S, Liu J, Akiba H, Yagita H, Atarashi K, Honda K, Roers A,
Muller W, Kurabayashi K, Hosoi-Amaike M, Takahashi N, Hirokawa M,
Matsushima K, Sawada K, Ohteki T. Immunity. 2013 ;39(3):584-98.
5) T-cell immunoglobulin and mucin domain 3 acts as a negative
regulator of atherosclerosis. Foks AC, Ran IA, Wasserman L, Frodermann
V, Ter Borg MN, de Jager SC, van Santbrink PJ, Yagita H, Akiba H, Bot
I, Kuiper J, van Puijvelde GH.
Arterioscler Thromb Vasc Biol. 2013;33(11):2558-65.
6) Galectin-9-mediated protection from allo-specific T cells as a
mechanism of immune privilege of corneal allografts. Shimmura-Tomita M,
Wang M, Taniguchi H, Akiba H, Yagita H, Hori J. PLoS One. 2013;8(5):e63620.
7) TIM-3 regulates innate immune cells to induce fetomaternal
tolerance. Chabtini L, Mfarrej B, Mounayar M, Zhu B, Batal I, Dakle PJ,
Smith BD, Boenisch O, Najafian N, Akiba H, Yagita H, Guleria I. J
Immunol. 2013;190(1):88-96.
8) Combined blockade of TIM-3 and TIM-4 augments cancer vaccine
efficacy against established melanomas. Baghdadi M, Nagao H, Yoshiyama
H, Akiba H, Yagita H, Dosaka-Akita H, Jinushi M. Cancer Immunol
Immunother. 2013;62(4):629-37.
2012
1) Blockade of CD70-CD27 interaction inhibits
induction of allergic lung inflammation in mice. Makino F, Ito J, Abe
Y, Harada N, Kamachi F, Yagita H, Takahashi K, Okumura K, Akiba H. Am J Respir Cell Mol Biol. 2012;47(3):298- 305.
2) Expression pattern changes and function of
RANKL during mouse lymph node microarchitecture development. Sugiyama
M, Nakato G, Jinnohara T, Akiba H, Okumura K, Ohno H, Yoshida H. Int Immunol. 2012;24(6):369-78.
3) Tumor-infiltrating DCs suppress nucleic
acid-mediated innate immune responses through interactions between the
receptor TIM-3 and the alarmin HMGB1. Chiba S, Baghdadi M, Akiba H,
Yoshiyama H, Kinoshita I, Dosaka-Akita H, Fujioka Y, Ohba Y, Gorman JV,
Colgan JD, Hirashima M, Uede T, Takaoka A, Yagita H, Jinushi M. Nat Immunol. 2012;13(9):832-42.
4) Antibodies against B7-DC with differential binding properties exert
opposite effects. Ritprajak P, Hashiguchi M, Akiba H, Yagita H, Okumura
K, Azuma M. Hybridoma. 2012;31(1):40-7.
5) Endogenous Tim-1 (Kim-1) promotes T-cell
responses and cell-mediated injury in experimental crescentic
glomerulonephritis. Nozaki Y, Nikolic-Paterson DJ, Snelgrove SL, Akiba
H, Yagita H, Holdsworth SR, Kitching AR. Kidney Int. 2012 ;81(9):844-55.
6) Galectin-9 and T cell immunoglobulin
mucin-3 pathway is a therapeutic target for type 1 diabetes. Kanzaki M,
Wada J, Sugiyama K, Nakatsuka A, Teshigawara S, Murakami K, Inoue K,
Terami T, Katayama A, Eguchi J, Akiba H, Yagita H, Makino H. Endocrinology. 2012;153(2):612-20.
2011
1) Anti-T cell immunoglobulin and mucin
domain-2 monoclonal antibody exacerbates collagen-induced arthritis by
stimulating B cells. Kawamoto T, Abe Y, Ito J, Makino F, Kojima Y, Usui
Y, Ma J, Morimoto S, Yagita H, Okumura K, Takasaki Y, Akiba H.
Arthritis Res Ther. 2011;13(2):R47.
2) TIM-1 signaling in B cells regulates
antibody production. Ma J, Usui Y, Takeda K, Harada N, Yagita H,
Okumura K, Akiba H. Biochem Biophys Res Commun. 2011; 406(2):223-8.
3) Tim-1 promotes cisplatin nephrotoxicity. Nozaki Y, Nikolic-Paterson DJ, Yagita H, Akiba H, Holdsworth SR, Kitching AR. Am J Physiol Renal Physiol. 2011;301(5): F1098-104.
4) Regulatory B cells are identified by
expression of TIM-1 and can be induced through TIM-1 ligation to
promote tolerance in mice. Ding Q, Yeung M, Camirand G, Zeng Q, Akiba
H, Yagita H, Chalasani G, Sayegh MH, Najafian N, Rothstein DM. J Clin Invest. 2011;121(9):3645-56.
5) Wound-induced TGF-β1 and TGF-β2
enhance airway epithelial repair via HB-EGF and TGF-α. Ito J, Harada N,
Nagashima O, Makino F, Usui Y, Yagita H, Okumura K, Dorscheid DR,
Atsuta R, Akiba H, Takahashi K. Biochem Biophys Res Commun. 2011;412(1):109-14.
6) Anti-TIM3 antibody promotes T cell
IFN-γ-mediated antitumor immunity and suppresses established tumors.
Ngiow SF, von Scheidt B, Akiba H, Yagita H, Teng MW, Smyth MJ. Cancer Res. 2011;71(10):3540-51.
7) The
TIM-1:TIM-4 pathway enhances renal ischemia-reperfusion injury. Rong S,
Park JK, Kirsch T, Yagita H, Akiba H, Boenisch O, Haller H, Najafian N,
Habicht A. J Am Soc Nephrol. 2011;22(3):484-95.
2010
1) TIM1 is an endogenous ligand for
LMIR5/CD300b: LMIR5 deficiency ameliorates mouse kidney
ischemia/reperfusion injury. Yamanishi Y, Kitaura J, Izawa K, Kaitani
A, Komeno Y, Nakamura M, Yamazaki S, Enomoto Y, Oki T, Akiba H, Abe T,
Komori T, Morikawa Y, Kiyonari H, Takai T, Okumura K, Kitamura T. J Exp
Med. 2010 ;207(7):1501-11.
2) Expression and function of inducible
costimulator on peripheral blood CD4+ T cells in Behcet's patients with
uveitis: a new activity marker? Usui Y, Takeuchi M, Yamakawa N,
Takeuchi A, Kezuka T, Ma J, Matsuda R, Okunuki Y, Akiba H, Goto H.
Invest Ophthalmol Vis Sci. 2010;51(10):5099-104.
3) TIM-3: a novel regulatory molecule of
alloimmune activation. Boenisch O, D'Addio F, Watanabe T, Elyaman W,
Magee CN, Yeung MY, Padera RF, Rodig SJ, Murayama T, Tanaka K, Yuan X,
Ueno T, Jurisch A, Mfarrej B, Akiba H, Yagita H, Najafian N. J Immunol.
2010;185(10):5806-19.
4) T-cell immunoglobulin mucin-3
determines severity of liver ischemia/reperfusion injury in mice in a
TLR4-dependent manner. Uchida Y, Ke B, Freitas MC, Yagita H, Akiba H,
Busuttil RW, Najafian N, Kupiec-Weglinski JW. Gastroenterology. 2010;139(6):2195-206.
5) Premature terminal exhaustion of
Friend virus-specific effector CD8+ T cells by rapid induction of
multiple inhibitory receptors. Takamura S, Tsuji-Kawahara S, Yagita H,
Akiba H, Sakamoto M, Chikaishi T, Kato M, Miyazawa M. J Immunol. 2010;184(9):4696-707.
6) Contribution of B7RP-1/ICOS
co-stimulation to lethal acute GVHD. Fujimura J, Takeda K, Kaduka Y,
Saito M, Akiba H, Yagita H, Yamashiro Y, Shimizu T, Okumura K. Pediatr Transplant. 2010;14(4):540-8.
7) The emerging role of T cell
immunoglobulin mucin-1 in the mechanism of liver ischemia and
reperfusion injury in the mouse. Uchida Y, Ke B, Freitas MC, Ji H, Zhao
D, Benjamin ER, Najafian N, Yagita H, Akiba H, Busuttil RW,
Kupiec-Weglinski JW. Hepatology. 2010;51(4):1363-72.
2009
1) Tim-3 mediates phagocytosis of apoptotic cells and cross-presentation.
Nakayama M, Akiba H, Takeda K, Kojima Y, Hashiguchi M, Azuma M, Yagita
H, Okumura K. Blood. 2009;113(16):3821-30.
2) RANKL is necessary and sufficient to initiate development of
antigen-sampling M cells in the intestinal epithelium. Knoop KA, Kumar
N, Butler BR, Sakthivel SK, Taylor RT, Nochi T, Akiba H, Yagita H,
Kiyono H, Williams IR. J Immunol. 2009 ;183(9):5738-47.
3) Targeting Tim-1 to overcome resistance to transplantation tolerance
mediated by CD8 T17 cells. Yuan X, Ansari MJ, D'Addio F, Paez-Cortez J,
Schmitt I, Donnarumma M, Boenisch O, Zhao X, Popoola J, Clarkson MR,
Yagita H, Akiba H, Freeman GJ, Iacomini J, Turka LA, Glimcher LH,
Sayegh MH. Proc Natl Acad Sci U S A. 2009;106(26):10734-9.
4) Roles of PU.1 in monocyte- and mast cell-specific gene regulation:
PU.1 transactivates CIITA pIV in cooperation with IFN-gamma. Ito T,
Nishiyama C, Nakano N, Nishiyama M, Usui Y, Takeda K, Kanada S,
Fukuyama K, Akiba H, Tokura T, Hara M, Tsuboi R, Ogawa H, Okumura K. Int Immunol. 2009;21(7):803-16.
5) RANK-RANKL signaling pathway is critically involved in the function
of CD4+CD25+ regulatory T cells in chronic colitis. Totsuka T, Kanai T,
Nemoto Y, Tomita T, Okamoto R, Tsuchiya K, Nakamura T, Sakamoto N,
Akiba H, Okumura K, Yagita H, Watanabe M. J Immunol. 2009;182(10):6079-87.
6) Suppression of experimental autoimmune uveoretinitis by regulatory
dendritic cells in mice. Usui Y, Takeuchi M, Hattori T, Okunuki Y,
Nagasawa K, Kezuka T, Okumura K, Yagita H, Akiba H, Goto H. Arch Ophthalmol. 2009;127(4):514-9.
7) Notch signaling confers antigen-presenting cell functions on mast
cells. Nakano N, Nishiyama C, Yagita H, Koyanagi A, Akiba H, Chiba S,
Ogawa H, Okumura K. J Allergy Clin Immunol. 2009;123(1):74-81.e1.
2008
1) B7-H3 contributes to the development of pathogenic Th2 cells in a
murine model of asthma. Nagashima O, Harada N, Usui Y, Yamazaki T,
Yagita H, Okumura K, Takahashi K, Akiba H. J Immunol. 2008;181(6):4062-71.
2) A novel ICOS-independent, but CD28- and SAP-dependent, pathway of T
cell-dependent, polysaccharide-specific humoral immunity in response to
intact Streptococcus pneumoniae versus pneumococcal conjugate vaccine.
Chen Q, Cannons JL, Paton JC, Akiba H, Schwartzberg PL, Snapper CM. J Immunol. 2008 ;181(12):8258-66.
3) The emerging role of T cell Ig mucin 1 in alloimmune responses in an
experimental mouse transplant model. Ueno T, Habicht A, Clarkson MR,
Albin MJ, Yamaura K, Boenisch O, Popoola J, Wang Y, Yagita H, Akiba H,
Ansari MJ, Yang J, Turka LA, Rothstein DM, Padera RF, Najafian N,
Sayegh MH. J Clin Invest. 2008 ;118(2):742-51.
4) Peritubular ischemia contributes more to tubular damage than
proteinuria in immune-mediated glomerulonephritis. Wong MG, Suzuki Y,
Tanifuji C, Akiba H, Okumura K, Sugaya T, Yamamoto T, Horikoshi S, Tan
SY, Pollock C, Tomino Y. J Am Soc Nephrol. 2008;19(2):290-7.
5) Roles of galectin-9 in the development of experimental allergic
conjunctivitis in mice. Fukushima A, Sumi T, Fukuda K, Kumagai N,
Nishida T, Okumura K, Akiba H, Yagita H, Ueno H. Int Arch Allergy Immunol. 2008;146(1):36-43.
2007以前
別紙参照